13-Tert-butoxycarbonylhydrazone of rubomycin was prepared on interaction of rubomycin with tert-butoxycarbonylhydrazine. The new compound showed a high antitumor activity with respect to lymphosarcoma LIO-1 and Garding-Passey melanoma. The compound had no advantages over the initial rubomycin in the treatment of these tumors, was inferior to rubomycin with respect to its activity against leukemia P-388 and unlike rubomycin had practically no effect on leukemia L-1210.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!